MSH Capital Advisors LLC Purchases 354 Shares of Johnson & Johnson $JNJ

MSH Capital Advisors LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 2.4% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 15,343 shares of the company’s stock after buying an additional 354 shares during the period. MSH Capital Advisors LLC’s holdings in Johnson & Johnson were worth $2,344,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Wealth Group Ltd. bought a new position in shares of Johnson & Johnson during the 1st quarter worth about $218,000. GAMMA Investing LLC increased its holdings in shares of Johnson & Johnson by 48.0% during the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after purchasing an additional 14,118 shares during the period. Davis Investment Partners LLC increased its holdings in shares of Johnson & Johnson by 7.9% during the 1st quarter. Davis Investment Partners LLC now owns 4,429 shares of the company’s stock worth $682,000 after purchasing an additional 326 shares during the period. Finally, Yarger Wealth Strategies LLC lifted its position in Johnson & Johnson by 6.2% in the first quarter. Yarger Wealth Strategies LLC now owns 1,560 shares of the company’s stock worth $259,000 after purchasing an additional 91 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several research reports. Sanford C. Bernstein raised their target price on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Barclays upped their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. HSBC upped their target price on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 target price on shares of Johnson & Johnson in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $192.94.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $190.66 on Friday. The firm has a market cap of $459.16 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $192.10. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company’s 50-day moving average price is $178.48 and its two-hundred day moving average price is $163.76.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.